CIRM Funds USC Heart Cell Therapy Development
A $6.9 million state grant will advance a USC-developed therapy designed to regenerate heart muscle after severe heart attacks.
Updated on Nov. 5, 2026 in Heart Disease
Live Poll
Do you think new medical treatments should be accessible to patients regardless of income?
The California Institute for Regenerative Medicine awarded $6.9 million to support preclinical development of a cardiac cell therapy created by USC Stem Cell scientists. The therapy is designed to regenerate cardiac muscle after a severe heart attack.
Why it matters
Severe heart attacks with cardiogenic shock carry high mortality, and the heart has very limited ability to regenerate damaged tissue. The funding aims to move the therapy toward human testing, which could offer a new option for patients with few current treatments.
The $6.9 million grant funds preclinical work, while one in four patients with myocardial infarction and cardiogenic shock dies within a week and half die within a month. Safety and effectiveness in humans remain untested, with human trials targeted for late 2027.
The players
California Institute for Regenerative Medicine (CIRM)
The California state-funded agency that supports stem cell and regenerative medicine research, providing the $6.9 million grant for this preclinical development.
USC Stem Cell
The University of Southern California research group whose scientists created the cardiac cell therapy and lead its development.
Marcus Foundation
A philanthropic organization that supports the clinical trial targeted for late 2027.
The details
The grant covers rigorous testing, process development, manufacturing and clinical planning for an off-the-shelf therapy that does not require customization for individual patients. Stem cells are banked, with a subset developed into cardiac muscle and frozen, and an artificial intelligence algorithm developed by Sanjeet Patel will identify trial participants most likely to benefit.
Timeline
November 5, 2026: CIRM grant announced for heart cell therapy development.
Late 2027: Targeted launch of human clinical trials at USC and the University of Washington.
Big Picture
The grant extends the California Institute for Regenerative Medicine's stem cell funding program into cardiac repair, following its support of regenerative therapies that aim to replace tissue the body cannot heal on its own. It moves a preclinical USC project toward human testing.
Patients who suffer severe heart attacks with cardiogenic shock currently face high short-term mortality with limited options. If this therapy proves safe and effective in trials, it could eventually offer a new treatment path, though it remains years from availability.
The takeaway
Regenerative therapies for heart damage remain experimental, and state funding is moving this USC therapy from the lab toward the human trials needed to test whether it can help patients with severe heart attacks.
What happens next
Human clinical trials of the cardiac cell therapy are targeted to launch in late 2027 at USC and the University of Washington.
Further reading
Explore more on Heart Disease research and treatment advances in California.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you think new medical treatments should be accessible to patients regardless of income?
